Investigation of the laxative, spasmolytic and prokinetic properties of aqueous methanol extract of Buxus sempervirens Linn (Buxaceae)
Purpose: To investigate the spasmolytic and laxative properties of Buxus sempervirens Linn (Buxaceae) in rabbits and mice.
Methods: Aqueous methanol extract (AqMeBS) as well as the dichloromethane (DCMF) and aqueous (AqF) fractions of Buxus sempervirens were investigated on isolated rabbit jejunum to explore its antispasmodic effect, relative to the standard drug, verapamil. Laxative and prokinetic potentials of 250 and 500 mg/kg doses of AqMeBS extract were evaluated in mice and compared to that of negative (normal saline) and positive (carbachol) control groups. The effects of AqMeBS and carbachol were also tested in mice pretreated with atropine (10 mg/kg). Single dose, acute oral toxicity study on AqMeBS was also executed in mice at 4000, 8000 and 12000 mg/kg doses.
Results: AqMeBS, DCMF and AqF significantly inhibited the rhythmic contractility of jejunum with 0.961, 0.0327 and 0.242 mg/mL, respectively, as median effective concentrations (EC50). In addition, AqMeBS, DCMF and AqF significantly relaxed the contractions due to K+, with EC50 of 1.85, 0.05 and 1.07 mg/mL, respectively. Ca2+ concentration response curves (CCRCs) were shifted to the right by AqMeBS and DCMF, in the same manner as verapamil. In the in vivo experiments, AqMeBS produced significant (p < 0.0001) laxative and prokinetic effects at 250 and 500 mg/kg doses and was comparable to that of carbachol. The acute toxicity study showed that AqMeBS was associated with one mortality at the highest tested dose (12000 mg/kg).
Conclusion: These results provide the pharmacological basis for the traditional use of B. sempervirens Linn as a laxative and prokinetic remedy in the management of constipation.
Keywords: Buxus sempervirens, Calcium channel blocker, Prokinetic, Laxative, Spasmolytic
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.